芦可替尼治疗JAK2V617F阳性骨髓增殖性肿瘤的临床效果  

Clinical effect of Ruxolitinib in the treatment of JAK2V617F-positive myeloproliferative neoplasms

作　　者：邹民[1] ZOU Min(Department of Hematology,Ganzhou People′s Hospital,Jiangxi Province,Ganzhou341000,China)

机构地区：[1]江西省赣州市人民医院血液内科,江西赣州341000

出　　处：《中国当代医药》2022年第2期79-81,共3页China Modern Medicine

基　　金：江西省卫生健康委科技计划项目(20202081)。

摘　　要：目的探讨芦可替尼治疗JAK2V617F阳性骨髓增殖性肿瘤(MPN)的临床效果。方法选取2017年7月至2019年7月赣州市人民医院收治的60例JAK2V617F阳性MPN患者作为研究对象,采用随机数字表法将其分为观察组和对照组,每组各30例。对照组患者采用羟基脲片口服治疗,观察组采用芦可替尼片口服治疗。比较两组患者治疗前后MPN总症状(MPN-10)评分、骨髓纤维化(MF)分级评估、脾长径和骨髓JAK2V617F基因相对表达水平,记录两组治疗期间不良反应发生情况。结果治疗后,观察组MPN-10评分、MF分级评分低于对照组,观察组脾长径短于对照组,差异有统计学意义(P<0.05)。治疗半年、1年,观察组的JAK2V617F基因相对表达量水平低于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论芦可替尼可明显降低JAK2V617F阳性MPN患者的JAK2V617F基因表达量,逆转骨髓纤维化水平,提高临床疗效。Objective To explore the clinical effect of Ruxolitinib in the treatment of JAK2V617F-positive myeloproliterative neoplasms(MPN).Methods A total of 60 JAK2V617F positive MPN patients admitted to Ganzhou People′s Hospital from July 2017 to July 2019 were selected as the study subjects,and they were divided into observation group and control group by random number table method,with 30 patients in each group.The control group was treated with oral Hydroxycarbamide Tablets,while observation group was treated with oral Ruxolitinib.Total MPN-10 score,myelofibrosis(MF)grading assessment,spleen diameter,relative expression levels of JAK2V617F gene in bone marrow were compared between two groups before and after treatment,and the occurrence of adverse reactions between two groups during treatment was recorded.Results After treatment,the MPN-10 and MF scores of the observation group were lower than those of the control group,and the spleen diameter of the observation group was shorter than that of the control group,the differences were statistically significant(P<0.05).The relative expression level of JAK2V617F gene in the observation group were lower than those in the control group after 6 months and 1 year of treatment,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Ruxolitinib can significantly reduce expression level of JAK2V617F gene in patients with JAK2V617F-positive MPN,reverse myelofibrosis level,and improve clinical curative effect.

关 键 词：芦可替尼 JACK2V617F基因 骨髓增殖性肿瘤 羟基脲片 

分 类 号：R738.1[医药卫生—肿瘤]